Independent directory Public ClinicalTrials.gov records United States
Condition Directory

Prostate Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Prostate Cancer. Browse Prostate Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 21, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 20, 2026, 9:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
3922
Shown on this page
12
Current sort
Recently updated
Condition scope
Prostate Cancer
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Prostate Cancer studies are organized in the registry

Prostate cancer studies are organized around disease-state vocabulary more than most cancers: “castration-resistant” (CRPC), “hormone-sensitive,” and “biochemical recurrence” mark distinct study populations and appear directly in listings. Active-surveillance research is typically registered as observational, so the study-type filter separates it cleanly.

Terms that often appear in related listings

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Prostate Cancer. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1321–1332 of 3,922 matching trials for Prostate Cancer.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Conditions
Prostate Cancer
Interventions
MRI-guided Transurethral Ultrasound Ablation
Device
Lead sponsor
Profound Medical Inc.
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more
Conditions
Prostate Cancer
Interventions
degarelix, enzalutamide, trametinib, dasatinib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Interventions
Relugolix, Abiraterone, Prednisone, Methylprednisolone, Apalutamide, Docetaxel
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Radical Prostatectomy, TULSA Procedure
Device
Lead sponsor
Profound Medical Inc.
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
19
States / cities
Chandler, Arizona • Mesa, Arizona • Scottsdale, Arizona + 14 more
Conditions
Ovarian, Breast, Prostate, Pancreatic, Advanced Tumours
Interventions
olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
2
States / cities
West Hollywood, California • Philadelphia, Pennsylvania
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Prostate Cancer
Interventions
Darolutamide (Nubeqa, BAY1841788), Enzalutamide, Apalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
13,779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Whippany, New Jersey
Conditions
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Durvalumab, Olaparib, Quality-of-Life Assessment, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
Interventions
XmAb®808, Keytruda® (pembrolizumab)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more
Conditions
Prostate Cancer
Interventions
BMS-986218 and Degarelix, Degarelix
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Dietary Intervention, Fasting
Procedure · Other · Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Prostate Cancer, Metastatic Prostate Cancer, Androgen Deprivation Therapy
Interventions
Telerehabilitation Intervention
Other
Lead sponsor
University of Utah
Other
Eligibility
21 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah

About this Prostate Cancer clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Prostate Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Prostate Cancer.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Prostate Cancer.